Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 700 shares at $7.00 ($5K) on 2014-10-20, disclosed to the SEC on 2014-10-21.
Scheduled sale ($5k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.04 | 400 | $3K | 57.3% |
| 2 | $7.00 | 300 | $2K | 42.7% |
| Total | $7.02 avg | 700 | $5K | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |